Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components |
| |
| Authors: | Fekete Natalie Gadelorge Mélanie Fürst Daniel Maurer Caroline Dausend Julia Fleury-Cappellesso Sandrine Mailänder Volker Lotfi Ramin Ignatius Anita Sensebé Luc Bourin Philippe Schrezenmeier Hubert Rojewski Markus Thomas |
| |
| Institution: | 1. Institut für Transfusionsmedizin, Universität Ulm und Institut für Klinische Transfusionsmedizin und Immungenetik Ulm, DRK-Blutspendedienst Baden-Württemberg-Hessen, Germany;2. Laboratoire de Thérapie Cellulaire, Etablissement Français du Sang–Pyrénées-Méditerranée Toulouse, France;3. Institut für Unfallchirurgische Forschung und Biomechanik, Universitätsklinikum Ulm, Germany;1. Military Medical Academy, Institute for Medical Research, Belgrade, Serbia;2. University of Nis, Medical Faculty, Nis, Serbia;3. University of Belgrade, Faculty of Biology, Belgrade, Serbia;4. University of Defense in Belgrade, Medical Faculty of the Military Medical Academy, Belgrade, Serbia;3. Institute of Anatomy, Musculoskeletal Research Group, Ludwig-Maximilian-University Munich, Pettenkoferstrasse 11, D-80336 Munich, Germany,;4. Investigating Institute of Molecular Biological System Transfer, Tehran 1417863171, Iran, and;5. Department of Parasitology, Faculty of Veterinary Medicine, University of Tehran, Tehran 141556453, Iran;1. Department of Orthopaedic, Trauma and Reconstructive Surgery, Charité-University of Medicine, Campus Benjamin Franklin, Berlin, Germany;2. Department of Otorhinolaryngology, Head and Neck Surgery, Charité-University of Medicine, Campus Benjamin Franklin, Berlin, Germany |
| |
| Abstract: | Background aimsThe clinical use of human mesenchymal stromal cells (MSC) requires ex vivo expansion in media containing supplements such as fetal bovine serum or, alternatively, human platelet lysate (PL).MethodsPlatelet concentrates were frozen, quarantine stored, thawed and sterile filtered to obtain PL. PL content and its effect on fibroblast–colony-forming unit (CFU-F) formation, MSC proliferation and large-scale expansion were studied.ResultsPL contained high levels of basic fibroblast growth factor (bFGF), soluble CD40L (sCD40L), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), platelet-derived growth factor AA (PDGF-AA), platelet-derived growth factor AB/BB (PDGF-AB/BB), chemokine (C-C) ligand 5 (CCL5; RANTES) transforming growth factor-β1 (TGF-β1) and chemokine (C-X-C) ligand 1/2/3 (GRO), with low batch-to-batch variability, and most were stable for up to 14 days. Inhibition of PDGF-BB and bFGF decreased MSC proliferation by about 20% and 50%, respectively. The strongest inhibition (about 75%) was observed with a combination of anti-bFGF + anti-PDGF-BB and anti-bFGF + anti-TGF-β1 + anti-PDGF-BB. Interestingly, various combinations of recombinant PDGF-BB, bFGF and TGF-β1 were not sufficient to promote cell proliferation. PL from whole blood-derived pooled platelet concentrates and apheresis platelet concentrates did not differ significantly in their growth-promoting activity on MSC.ConclusionsPL enhances MSC proliferation and can be regarded as a safe tool for MSC expansion for clinical purposes. \in particular, PDGF-BB and bFGF are essential components for the growth-promoting effect of PL, but are not sufficient for MSC proliferation. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
